Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.HemaQuest Pharmaceuticals has reported that following FDA's acceptance of its investigational new drug application, it has started a Phase I clinical trial of its orally administered, patented therapeutic, HQK-1001 that is being developed to treat the two most common inherited blood diseases, sickle cell anemia and thalassemia.
Subscribe to our email newsletter
The Phase I clinical study is being carried out in healthy volunteers, who will receive increasing doses of HQK-1001 to evaluate its safety and pharmacokinetics in anticipation of future clinical trials in patients with these hemoglobin disorders.
Ronald Berenson, president and CEO of HemaQuest, said: “We are committed to continuing the rapid development path for HQK-1001, which has the potential to be a major advance in treating serious and life-threatening blood disorders.”